Top ▲
target has curated data in GtoImmuPdb
Target id: 1884
Nomenclature: TWEAK receptor
Systematic Nomenclature: TNFRSF12A
Gene and Protein Information  |
||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | 1 | 129 | 16p13.3 | TNFRSF12A | TNF receptor superfamily member 12A | |
| Mouse | 1 | 129 | 17 A3.3 | Tnfrsf12a | tumor necrosis factor receptor superfamily, member 12a | |
| Rat | - | - | Tnfrsf12a | TNF receptor superfamily member 12A | ||
| Previous and Unofficial Names |
| Fn14 | tumor necrosis factor receptor superfamily, member 12a | CD266 | FGF-inducible 14 | TweakR | tumor necrosis factor receptor superfamily, member 12A | tumor necrosis factor receptor superfamily |
| Database Links |
|
| Alphafold | Q9NP84 (Hs), Q9CR75 (Mm) |
| ChEMBL Target | CHEMBL3712850 (Hs) |
| Ensembl Gene | ENSG00000006327 (Hs), ENSMUSG00000023905 (Mm), ENSRNOG00000003546 (Rn) |
| Entrez Gene | 51330 (Hs), 27279 (Mm), 302965 (Rn) |
| Human Protein Atlas | ENSG00000006327 (Hs) |
| KEGG Gene | hsa:51330 (Hs), mmu:27279 (Mm), rno:302965 (Rn) |
| OMIM | 605914 (Hs) |
| Pharos | Q9NP84 (Hs) |
| UniProtKB | Q9NP84 (Hs), Q9CR75 (Mm) |
| Wikipedia | TNFRSF12A (Hs) |
| Natural/Endogenous Ligands |
| TWEAK {Sp: Human} |
| Adaptor proteins (Human) |
| TRAF1, TRAF2, TRAF3 |
| Other Binding Ligands | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| The protein product of the TNFRSF12A gene (fibroblast growth factor-inducible 14, or TWEAK receptor) is a receptor for the endogenous ligand TNF-like weak inducer of apoptosis (TWEAK). TWEAK receptor expression is upregulated in response to tissue injury. TWEAK receptor activation results in modulation of expression of NF-κB-regulated genes associated with the resolution of tissue damage. Because of its proinflammatory signalling profile the TWEAK receptor/TWEAK system has been implicated in a number of pathologies, and is therefore considered a potential drug target for conditions including muscle atrophy, cerebral ischaemia [2], kidney injury, atherosclerosis and infarction, cancer, and autoimmune conditions such as autoimmune encephalitis, rheumatoid arthritis and inflammatory bowel disease [5]. An anti-TWEAK receptor monoclonal antibody (PDL192, enavatuzumab) has completed Phase 1 clinical trial (NCT00738764) in solid tumours [4] as a novel immuno-oncology therapeutic [1]. A TWEAK receptor targeting immunotoxin (PE38-P4A8, a fusion protein containing an anti-TWEAK receptor antibody scFv chain and the bacterial Pseudomonas exotoxin PE38) with anti-tumour activity has also been reported [3]. |
| Immuno Process Associations | ||
|
1. Culp PA, Choi D, Zhang Y, Yin J, Seto P, Ybarra SE, Su M, Sho M, Steinle R, Wong MH et al.. (2010) Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms. Clin Cancer Res, 16 (2): 497-508. [PMID:20068083]
2. Haile WB, Echeverry R, Wu F, Guzman J, An J, Wu J, Yepes M. (2010) Tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 mediate cerebral ischemia-induced poly(ADP-ribose) polymerase-1 activation and neuronal death. Neuroscience, 171 (4): 1256-64. [PMID:20955770]
3. Keshtvarz M, Salimian J, Yaseri M, Bathaie SZ, Rezaie E, Aliramezani A, Norouzbabaei Z, Amani J, Douraghi M. (2017) Bioinformatic prediction and experimental validation of a PE38-based recombinant immunotoxin targeting the Fn14 receptor in cancer cells. Immunotherapy, 9 (5): 387-400. [PMID:28357912]
4. Purcell JW, Kim HK, Tanlimco SG, Doan M, Fox M, Lambert P, Chao DT, Sho M, Wilson KE, Starling GC et al.. (2014) Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR. Front Immunol, 4: 505. [PMID:24409185]
5. Xu WD, Zhao Y, Liu Y. (2016) Role of the TWEAK/Fn14 pathway in autoimmune diseases. Immunol Res, 64 (1): 44-50. [PMID:26659091]
